Details up front: 5 mg · six weeks · fatigue.
I suspect the usual explanation for this is wrong, or at least incomplete.
I am aware this may have a boring answer. I would still like the boring answer stated clearly.
Can someone derive this rather than assert it?
six weeks at 5 mg is 42 days at one dose level — and the arithmetic the question hides is that it also moves every dose above 5 mg back by 42 days. Whether that reduces fatigue depends on which quantity it tracks. A symptom driven by the dose itself is unchanged by waiting: 5 mg is 5 mg on day 1 and on day 42. A symptom driven by the rate of change has 42 days of no change to settle in, which is the case the hold is actually made for. The distinction is testable on your own record: plot fatigue against days-since-last-increase rather than against dose, and if the peaks line up with the increases the hold is doing something. Escalation schedules are set by a prescriber, and nothing here is medical advice.
The short version: four-weekly steps for the weekly agents, hold rather than escalate when symptoms are active, and slower is always available.
For an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.
The published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.
Titration schedules in the licensed products were designed specifically to manage gastrointestinal tolerability, and that intent is stated in the clinical development literature.
Slower costs time and nothing else. The ceiling is the same.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsStart with the half-life, because the interval between steps should be at least four half-lives or you are escalating before the previous step has expressed itself.
Holding a step for eight weeks instead of four is a legitimate approach with no efficacy cost at the destination, and it is what the trials effectively did for anyone who tolerated poorly.
Put another way, the dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.
Faster titration does not reach the destination sooner in any way that matters; it reaches the symptoms sooner.
Hold rather than escalate while symptoms are active. Always.
edited 22 Jan 2025 by Dr_Marek_Zielinski — tightened the wording; no substantive change
The relevant arithmetic is that steady state takes four to five half-lives, so a one-week half-life means a four-week step interval and nothing shorter is informative.
Escalating while gastrointestinal symptoms are still active is the commonest avoidable error. Tolerance to the previous step has not developed, and the new step lands on top of it.
Liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.
Four to five half-lives to steady state is standard first-order pharmacokinetics and gives the four-week interval directly from the one-week half-life.
A schedule described here is a published schedule for a licensed product and is not a recommendation.
Four half-lives between steps, minimum. Work it out for your agent.
Answering this needs the agent and the current step, since the schedules differ and the reason they differ is pharmacokinetic.
Titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.
Stepping back is a normal adjustment, not a failure.
The honest answer is that going slower costs time and nothing else, since the exposure ceiling is unchanged.
The published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.
Trial data show gastrointestinal adverse events concentrated in the escalation phase and declining at stable doses.
The caveat is that titration decisions belong with a clinician who knows what else is on board.
The top of the schedule is not the target. The working dose is.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.